Brüstle v. Greenpeace, decided by the Court of Justice of the European Union, or CJEU, on October 18, 2011, changes the landscape of patent law in the European Union. Brüstle was referred from the Bundesgerichtshof, Germany’s Federal Court of Justice, to the CJEU for guidance on the meaning of “human embryo” in Directive 98/44/EC on the legal protection of biotechnological inventions (hereinafter Directive).
Share this article
View the original article here: European Court Decision has Big Implications for Stem Cell Research
